Opportunity Assessment
Validate clinical demand for AI diagnostics in a new market. Covers specialist physician and hospital administrator interviews, SaMD regulatory mapping, reimbursement research, and a Go/Defer/Kill recommendation.
Learn more →
Our POV · 2026
AI-powered diagnostics and pathology market entry strategy
AI-powered diagnostics is transforming clinical medicine – with computational pathology, AI radiology, AI dermatology, and AI ophthalmology all demonstrating clinical performance comparable to specialists in specific diagnostic tasks. AI diagnostics companies are expanding into Southeast Asia, South Asia, and the Gulf as healthcare system staffing shortfalls, AI regulatory approval acceleration, and hospital technology investment create commercial deployment conditions. GreyRadius helps AI diagnostics businesses validate clinical demand, navigate SaMD regulatory pathways, and raise capital.
Why now? Diagnostic workforce shortages are the primary AI diagnostics driver – the WHO estimates a shortage of 2.4 million healthcare workers by 2030, with pathologists and radiologists among the most acutely shortage-affected specialties. Markets with the largest diagnostic staffing gaps offer the most compelling AI diagnostics value propositions. Regulatory approval for AI medical devices is accelerating – CDSCO in India, HSA in Singapore, and Gulf health authorities are all establishing clearer AI SaMD pathways.
$45B+
AI diagnostics market by 2030
Growing at 45% annually as clinical validation accumulates, regulatory approvals accelerate, and hospital AI investment increases.
30+
Primary interviews per AI diagnostics mandate
Radiologists, pathologists, and hospital administrators – every engagement grounded in direct primary research.
8 weeks
Market entry strategy delivery
AI-augmented SaMD regulatory mapping and clinical demand research delivers AI diagnostics market entry strategies efficiently.
Market Intelligence
What the data says.
AI diagnostics market is projected to reach $45B by 2030 – growing at 45% annually as clinical validation accumulates, regulatory approvals accelerate, and hospital technology investment increases.
AI radiology is achieving clinical deployment scale – AI systems for chest X-ray, CT scan, and MRI interpretation are commercially deployed in thousands of hospitals globally and achieving reimbursement in multiple markets.
Computational pathology is reaching commercial deployment – whole slide imaging combined with AI analysis is reducing pathology turnaround time by 50%+ and improving diagnostic consistency.
AI ophthalmology is achieving remarkable commercial success – AI systems for diabetic retinopathy screening are commercially deployed at scale in India, China, and several Southeast Asian markets with strong clinical evidence.
Market Reality
What makes this market hard.
- SaMD regulatory pathway varies by market – AI diagnostic tools face different classification, clinical evidence, and approval requirements across FDA, CE, CDSCO, NMPA, and other regulatory frameworks.
- Hospital EMR and PACS integration is complex – AI diagnostic tools must integrate with hospital information systems that vary significantly by institution and vendor.
- Clinical champion development is critical – AI diagnostics adoption requires clinician champions who have validated the technology and advocate for it within hospital networks.
- Reimbursement for AI diagnostics is still developing – while clinical evidence is accumulating, insurance and government payer coverage for AI-interpreted diagnostics is not yet established in most markets.
Our Work
What we solve for clients.
If you recognise your situation below, we can help.
Clinical demand and hospital system validation
You need to validate which clinical specialties and hospital systems are actively seeking AI diagnostic tools and what evidence and integration requirements they have.
SaMD regulatory classification and approval
You need to understand how your AI diagnostic tool is classified and what clinical performance data and regulatory approval processes apply in each target market.
Clinical KOL and hospital partner identification
You need to identify radiology departments, pathology networks, and clinical AI champions as validation and early adoption partners.
GTM for an AI diagnostics company
You have an AI radiology, pathology, or diagnostic tool and need a go-to-market strategy.
Raising capital for an AI diagnostics venture
You are raising investment and need a pitch book grounded in clinical validation data and market sizing.
Reimbursement and payer strategy
You need to develop a reimbursement pathway strategy for each target market to enable payer-supported hospital adoption.
Our Services
How we engage.
Every engagement is grounded in primary research and delivers a measurable outcome.
Feasibility & TEV
Full financial and operational feasibility for AI diagnostics investments. Covers hospital adoption modelling, integration cost, revenue model, and investor-ready projections.
Learn more →Market Entry Execution
End-to-end market entry for AI diagnostics companies. Regulatory pathway, KOL identification, hospital ICP, and first-clinical-deployment milestone.
Learn more →GTM Execution-as-a-Service
Embedded GTM team for AI diagnostics platforms. Hospital and laboratory outreach, clinical champion engagement, and first-commercial-deployment milestone.
Learn more →Pitchbook & Fundraising
Investor-ready pitch books for AI diagnostics ventures. Clinical-demand-validated market sizing, regulatory approval narrative, and investor identification.
Learn more →AI Consulting
AI strategy – identifying which diagnostic applications offer the fastest path to regulatory approval, clinical adoption, and commercial deployment in each target market.
Learn more →Why GreyRadius.
Primary research-led
80% of our insight comes from first-party interviews with buyers, competitors, and regulators – not secondary data that everyone else has.
Expert-led, AI-enabled delivery
Our AI layer compresses research timelines by 60% and surfaces pattern-matching from 200+ prior mandates – so you get faster, deeper answers.
Outcomes, not reports
We measure success by first contracts signed, capital raised, and markets entered – not deliverables produced. Every mandate has a milestone.
200+
Projects delivered
100+
SaaS & tech clients
80%
Primary research-led
4
Countries / offices
Case Studies
Mandates we've run.
Diagnostics · Market Entry
Market entry for a diagnostics chain into 3 Gulf markets
Regulatory mappedSite surveyPartnership model
View all case studies →
Diagnostics · Assessment
Opportunity assessment for a home-diagnostics platform in India
Consumer researchCompetitor mappedUnit economics
View all case studies →
Diagnostics · GTM
GTM for a point-of-care diagnostics device in Southeast Asia
Distributor networkFirst contractsClinical validation
View all case studies →
FAQ
Common questions.
Does GreyRadius work with AI radiology companies or also with AI pathology, AI ophthalmology, and AI dermatology companies?+
All diagnostic specialties. We work with AI radiology, pathology, ophthalmology, dermatology, and multi-modal AI diagnostics companies across market entry, GTM, and fundraising.
What AI diagnostics markets does GreyRadius cover?+
Southeast Asia, South Asia, and the Gulf – markets with significant diagnostic workforce shortages and growing hospital AI investment.
How long does an AI diagnostics market entry engagement take?+
Typically 8–12 weeks for clinical demand research, SaMD regulatory mapping, and reimbursement landscape assessment.
Can GreyRadius identify clinical champion hospitals for AI diagnostics companies?+
Yes. Clinical KOL and reference hospital identification are part of our market entry execution service.
Stay informed
Market intelligence for Diagnostics leaders.
GreyRadius research notes, market entry signals, and sector briefs – delivered weekly. No fluff.
Not sure which engagement fits? Take our free 2-minute diagnostic →
Related market entry guides
Ready to enter this market?
Primary research. AI-enabled analysis, expert-reviewed. Outcomes-based delivery – across Gulf, Southeast Asia, South Asia.
Book a call